Analyst William Plovanic from Canaccord Genuity maintained a Buy rating on TransMedics Group (TMDX – Research Report) and keeping the price target at $104.00.
William Plovanic has given his Buy rating due to a combination of factors including the strong performance of TransMedics Group in the organ transplant market, particularly in the DCD (donation after circulatory death) segment. The recent data from UNOS indicates a significant increase in transplant volumes for heart, liver, and lung, which suggests that TransMedics is likely to exceed revenue expectations for Q1/25. The company has shown resilience and growth in the DCD market, especially with liver transplants, which were up 19% quarter-over-quarter.
Plovanic notes that even in a volatile market, TransMedics’ performance is closely tied to the expanding DCD market, where it has established a strong presence. The analyst believes that the company’s ability to gain market share in this segment positions it well for future growth, making it a solid investment choice. Additionally, the limited exposure to overseas markets and the critical nature of its end market provide a buffer against broader economic uncertainties, further supporting the Buy recommendation.
In another report released on April 2, Piper Sandler also maintained a Buy rating on the stock with a $90.00 price target.
TMDX’s price has also changed moderately for the past six months – from $134.235 to $86.840, which is a -35.31% drop .